TipRanks
Advertisement
Advertisement

STOK Stock Latest News

Stoke Therapeutics announces presentations of data for STK-002
The FlyStoke Therapeutics announces presentations of data for STK-002
9d ago
STOK
Stoke Therapeutics announces two presentations of data for STK-002 at AAO
PremiumThe Fly
Stoke Therapeutics announces two presentations of data for STK-002 at AAO
15d ago
STOK
Camp4 Therapeutics initiated with an Outperform at Oppenheimer
PremiumThe Fly
Camp4 Therapeutics initiated with an Outperform at Oppenheimer
16d ago
CAMP
STOK
Stoke completes meeting with FDA to align aspects with NDA for zorevunersen
PremiumThe Fly
Stoke completes meeting with FDA to align aspects with NDA for zorevunersen
16d ago
STOK
Stoke Therapeutics appoints new independent board director
PremiumCompany Announcements
Stoke Therapeutics appoints new independent board director
26d ago
8K
STOK
Stoke Therapeutics names Bo Cumbo to board of directors
PremiumThe FlyStoke Therapeutics names Bo Cumbo to board of directors
28d ago
STOK
Stoke Therapeutics, Biogen present long-term data on Zorevunersen
Premium
The Fly
Stoke Therapeutics, Biogen present long-term data on Zorevunersen
2M ago
BIIB
STOK
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
Premium
The Fly
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
2M ago
BIIB
STOK
Stoke Therapeutics reinstated with an Overweight at JPMorgan
PremiumThe Fly
Stoke Therapeutics reinstated with an Overweight at JPMorgan
2M ago
STOK
Stoke Therapeutics Charts Path From EMPEROR To Launch
PremiumCompany Announcements
Stoke Therapeutics Charts Path From EMPEROR To Launch
3M ago
STOK
Analyst Affirms Buy on Stoke Therapeutics as Phase 3 EMPEROR Trial Progress and Strong Cash Position Support Clear Path to 2028 Launch
PremiumRatings
Analyst Affirms Buy on Stoke Therapeutics as Phase 3 EMPEROR Trial Progress and Strong Cash Position Support Clear Path to 2028 Launch
3M ago
STOK
Stoke Therapeutics: Buy Rating Reaffirmed with Strong Balance Sheet, Clinical Progress, and Unchanged $44 Price Target
PremiumRatings
Stoke Therapeutics: Buy Rating Reaffirmed with Strong Balance Sheet, Clinical Progress, and Unchanged $44 Price Target
3M ago
STOK
Yaron Werber Reaffirms Buy on Strengthening Zorevunersen Outlook in Dravet Syndrome, Lifts Peak Sales View to $3B and Sets New $60 Price Target
PremiumRatingsYaron Werber Reaffirms Buy on Strengthening Zorevunersen Outlook in Dravet Syndrome, Lifts Peak Sales View to $3B and Sets New $60 Price Target
3M ago
STOK
Thomas Shrader Reaffirms Buy Rating on Zorevunersen Developer with Unchanged $39 Price Target, Citing Strong Phase 3 Outlook and Compelling Clinical Profile
Premium
Ratings
Thomas Shrader Reaffirms Buy Rating on Zorevunersen Developer with Unchanged $39 Price Target, Citing Strong Phase 3 Outlook and Compelling Clinical Profile
3M ago
STOK
Stoke Therapeutics: Strong Zorevunersen Trial Progress and Regulatory Visibility Support Buy Rating; Price Target Reaffirmed at $40
Premium
Ratings
Stoke Therapeutics: Strong Zorevunersen Trial Progress and Regulatory Visibility Support Buy Rating; Price Target Reaffirmed at $40
3M ago
STOK
Stoke Therapeutics price target lowered to $58 from $60 at Canaccord
PremiumThe Fly
Stoke Therapeutics price target lowered to $58 from $60 at Canaccord
3M ago
STOK
Stoke Therapeutics Expands ATM Equity Program for Funding
PremiumCompany Announcements
Stoke Therapeutics Expands ATM Equity Program for Funding
3M ago
8K
STOK
Stoke Therapeutics reports Q2 EPS (93c), consensus (78c)
PremiumThe Fly
Stoke Therapeutics reports Q2 EPS (93c), consensus (78c)
3M ago
STOK
Stoke Therapeutics (STOK) Q2 Earnings Cheat Sheet
PremiumPre-Earnings
Stoke Therapeutics (STOK) Q2 Earnings Cheat Sheet
3M ago
STOK
Stoke Therapeutics appoints McCauley as Chief Scientific Officer
PremiumThe FlyStoke Therapeutics appoints McCauley as Chief Scientific Officer
3M ago
STOK
Stoke Therapeutics initiated with a Buy at Goldman Sachs
Premium
The Fly
Stoke Therapeutics initiated with a Buy at Goldman Sachs
3M ago
STOK
Stoke Therapeutics Completes Enrollment in Phase 3 Dravet Trial
Premium
Company Announcements
Stoke Therapeutics Completes Enrollment in Phase 3 Dravet Trial
4M ago
8K
STOK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >